Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1/2 2

Status

Completed 2Terminated 1Active not recruiting 1

Sponsor Class

INDUSTRY 3OTHER 1

Study Type

Interventional 4

Sponsor

Cancer Type

Genitourinary 3Sarcoma 1

Conditions

Carcinoma, Non-Small-Cell Lung 74Breast Neoplasms 70Rectal Neoplasms 51Stomach Neoplasms 45Glioblastoma 45Esophageal Neoplasms 41Colorectal Neoplasms 37Lung Neoplasms 35Brain Neoplasms 35Squamous Cell Carcinoma of Head and Neck 32Pancreatic Neoplasms 31Glioma 27Neoplasms 26Sarcoma 24Neoplasm Metastasis 23Astrocytoma 22Head and Neck Neoplasms 21Carcinoma, Hepatocellular 19Esophageal Squamous Cell Carcinoma 16Colonic Neoplasms 16Recurrence 15Ovarian Neoplasms 15Melanoma 15Gliosarcoma 15Central Nervous System Neoplasms 15Urinary Bladder Neoplasms 13Oligodendroglioma 13Uterine Cervical Neoplasms 12Adenocarcinoma Of Esophagus 12Prostatic Neoplasms 11

Interventions

pembrolizumab 189Cisplatin 47Paclitaxel 45Carboplatin 44lenvatinib 31Docetaxel 23Pemetrexed 21Fluorouracil 20Capecitabine 17Gemcitabine 15Oxaliplatin 14Saline Solution 13Albumin-Bound Paclitaxel 11130-nm albumin-bound paclitaxel 10epacadostat 9Leucovorin 9Cetuximab 9olaparib 7Irinotecan 7Bevacizumab 7Etoposide 6enzalutamide 5durvalumab 5belzutifan 5Nivolumab 5Dexamethasone 5Surgical Procedures, Operative 4Radiotherapy 4trifluridine tipiracil drug combination 3spartalizumab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
Parkinson Disease 4, Autosomal Dominant Lewy Body × Surgical Procedures, Operative × Clear all
NCT03924856 2026-05-28

KEYNOTE-866

Merck Sharp & Dohme LLC

Phase 3 Completed
907 enrolled
Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Urinary Bladder Neoplasms

NCT04700124 2026-02-05

KEYNOTE-B15

Merck Sharp & Dohme LLC

Phase 3 Completed
808 enrolled
Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Urinary Bladder Neoplasms

NCT06305767 2026-01-13

INTerpath-005

Merck Sharp & Dohme LLC

Phase 1/2 Active not recruiting
230 enrolled
Genitourinary

Parkinson Disease 4, Autosomal Dominant Lewy Body, Urinary Bladder Neoplasms

NCT03116529 2024-11-04

NEXIS

University of Maryland, Baltimore

Phase 1/2 Terminated
22 enrolled
Sarcoma

Diabetes Mellitus, Insulin-Dependent, 12, Parkinson Disease 4, Autosomal Dominant Lewy Body, Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡